Published in J Exp Med on April 07, 2008
Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding protein. Proc Natl Acad Sci U S A (2008) 1.13
A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol (2010) 1.12
Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking. J Exp Med (2010) 1.11
Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine (2009) 1.08
Monkeypox virus and insights into its immunomodulatory proteins. Immunol Rev (2008) 1.07
Subversion of cytokine networks by virally encoded decoy receptors. Immunol Rev (2012) 0.98
Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver. PLoS Pathog (2012) 0.91
Crosstalk between the type 1 interferon and nuclear factor kappa B pathways confers resistance to a lethal virus infection. Cell Host Microbe (2013) 0.88
A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants. PLoS One (2009) 0.87
The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon. FASEB J (2009) 0.86
CD4+ T cell help is dispensable for protective CD8+ T cell memory against mousepox virus following vaccinia virus immunization. J Virol (2014) 0.85
The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responses. J Virol (2011) 0.83
Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease. Virol J (2011) 0.83
Loss of cytoskeletal transport during egress critically attenuates ectromelia virus infection in vivo. J Virol (2012) 0.82
The genome sequence of ectromelia virus Naval and Cornell isolates from outbreaks in North America. Virology (2014) 0.81
Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses. FASEB J (2011) 0.81
New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens. Virology (2009) 0.80
Elucidating the role of the complement control protein in monkeypox pathogenicity. PLoS One (2012) 0.80
Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS One (2012) 0.79
Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model. Clin Vaccine Immunol (2010) 0.78
Memory CD8⁺ T cells can outsource IFN-γ production but not cytolytic killing for antiviral protection. Cell Host Microbe (2013) 0.78
Sequential Activation of Two Pathogen-Sensing Pathways Required for Type I Interferon Expression and Resistance to an Acute DNA Virus Infection. Immunity (2015) 0.78
Evidence for Persistence of Ectromelia Virus in Inbred Mice, Recrudescence Following Immunosuppression and Transmission to Naïve Mice. PLoS Pathog (2015) 0.77
Impact of distinct poxvirus infections on the specificities and functionalities of CD4+ T cell responses. J Virol (2014) 0.77
Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses. J Virol (2014) 0.77
TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines. PLoS One (2014) 0.76
Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections. Viruses (2010) 0.76
RNA-Seq Based Transcriptome Analysis of the Type I Interferon Host Response upon Vaccinia Virus Infection of Mouse Cells. J Immunol Res (2017) 0.75
Infection with diverse immune-modulating poxviruses elicits different compositional shifts in the mouse gut microbiome. PLoS One (2017) 0.75
The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy. J Virol (2013) 0.75
Ectromelia virus accumulates less double-stranded RNA compared to vaccinia virus in BS-C-1 cells. Virology (2017) 0.75
Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol (1963) 29.15
Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92
Immune response in mice that lack the interferon-gamma receptor. Science (1993) 12.15
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol (2001) 8.31
Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol (2005) 7.74
Duration of antiviral immunity after smallpox vaccination. Nat Med (2003) 7.39
Type I interferons in host defense. Immunity (2006) 7.32
Viruses and interferons. Annu Rev Microbiol (2001) 7.12
Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol (2003) 5.51
Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol (1980) 4.24
Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol (1995) 4.16
The formation and function of extracellular enveloped vaccinia virus. J Gen Virol (2002) 4.14
Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med (2002) 3.86
Mechanisms of recovery from a generalized viral infection: mousepox. II. Passive transfer of recovery mechanisms with immune lymphoid cells. J Exp Med (1971) 3.74
Mouse-pox; infectious ectromelia of mice; a review. J Immunol (1949) 3.67
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell (1995) 3.51
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol (1973) 3.19
Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol (2003) 3.16
Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev (1995) 2.97
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol (2004) 2.72
Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis (2003) 2.46
Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature (1987) 2.45
Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol (1996) 2.35
Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus. J Gen Virol (1971) 2.35
Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol (1996) 2.32
Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem (1995) 2.27
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology (2000) 2.16
Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology (1999) 2.15
Cytokines and immunity to viral infections. Immunol Rev (1997) 2.13
Importance of interferons in recovery from mousepox. J Virol (1993) 2.12
Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics (2007) 2.10
The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol (2000) 2.08
Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology (2003) 2.07
Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol (1995) 2.07
Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J Virol (2000) 2.03
Vaccinia virus host range genes. Virology (1990) 2.02
Ectromelia virus: the causative agent of mousepox. J Gen Virol (2005) 1.99
Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis (2005) 1.82
The cell-mediated immune response to ectromelia virus infection. II. Secondary response in vitro and kinetics of memory T cell production in vivo. Cell Immunol (1976) 1.76
The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range. Virology (2002) 1.76
Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep (2003) 1.76
A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog (2008) 1.72
Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med (2006) 1.64
Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol (2005) 1.64
Induction of natural killer cell responses by ectromelia virus controls infection. J Virol (2007) 1.62
Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol (2004) 1.59
Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene. Virology (1992) 1.56
Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res (2007) 1.55
Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus. Arch Virol (1989) 1.53
Immunology 101 at poxvirus U: immune evasion genes. Semin Immunol (2001) 1.48
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine (2006) 1.43
Host-related immunomodulators encoded by poxviruses and herpesviruses. Curr Opin Microbiol (2000) 1.38
Neutralizing activities of antisera to poxvirus soluble antigens. J Gen Virol (1974) 1.36
Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host. J Immunol (2006) 1.34
The genomic sequence of ectromelia virus, the causative agent of mousepox. Virology (2003) 1.33
Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett (2001) 1.32
Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology (2005) 1.32
A cowpox virus gene required for multiplication in Chinese hamster ovary cells. J Virol (1988) 1.31
Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection. Proc Natl Acad Sci U S A (2007) 1.31
A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J Gen Virol (2002) 1.30
Analysis of the monkeypox virus genome. Virology (2002) 1.27
Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J Gen Virol (1991) 1.26
Fifty years of interferon research: aiming at a moving target. Immunity (2006) 1.22
Interferon function is not required for recovery from a secondary poxvirus infection. Proc Natl Acad Sci U S A (2005) 1.21
Vaccinia necrosum and its relationship to impaired immunologic responsiveness. Am J Med (1972) 1.17
Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol (2004) 1.16
Inhibition of interferons by ectromelia virus. J Virol (2002) 1.15
Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol Cell Biol (2007) 1.08
Inactivated smallpox vaccine. A comparison of inactivation methods. J Hyg (Lond) (1970) 1.02
Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection. J Virol (2007) 0.97
Poxvirus immune modulators: functional insights from animal models. Virus Res (2002) 0.94
Identification and nucleotide sequence of the gene encoding a surface antigen induced by vaccinia virus. Virology (1990) 0.88
Induction of skin resistance to vaccinia virus in rabbits by vaccinia-soluble early antigens. J Exp Med (1973) 0.81
Monkeypox in the United States: an occupational health look at the first cases. AAOHN J (2004) 0.80
Monkeypox in the Western hemisphere. N Engl J Med (2004) 0.78
Crystal structure of glycoprotein B from herpes simplex virus 1. Science (2006) 5.57
Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med (2012) 3.93
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20
Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J (2005) 2.95
Marked loss of myelinated nerve fibers in the human brain with age. J Comp Neurol (2003) 2.94
Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol (2010) 2.45
Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. Proc Natl Acad Sci U S A (2007) 2.43
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity (2004) 2.13
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J Virol (2005) 2.07
Herpes virus fusion and entry: a story with many characters. Viruses (2012) 2.05
Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM). J Virol (2002) 2.03
Mechanistic logic underlying the axonal transport of cytosolic proteins. Neuron (2011) 2.00
Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry. J Virol (2003) 1.92
Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J Virol (2010) 1.91
The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry. Proc Natl Acad Sci U S A (2004) 1.89
CD94 is essential for NK cell-mediated resistance to a lethal viral disease. Immunity (2011) 1.87
Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol (2005) 1.85
A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci (2010) 1.80
Phosphine-triggered synthesis of functionalized cyclic compounds. Chem Soc Rev (2008) 1.80
Mutational evidence of internal fusion loops in herpes simplex virus glycoprotein B. J Virol (2007) 1.79
Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface. J Virol (2003) 1.78
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog (2008) 1.72
Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr Opin Struct Biol (2008) 1.72
Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol (2010) 1.70
Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops. J Virol (2009) 1.65
Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol (2005) 1.64
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res (2011) 1.62
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions. J Virol (2007) 1.56
Reliable, verifiable and efficient monitoring of biodiversity via metabarcoding. Ecol Lett (2013) 1.56
Enhanced NK-cell development and function in BCAP-deficient mice. Blood (2008) 1.53
Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem (2002) 1.53
Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog (2011) 1.53
Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol (2003) 1.49
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans. Diabetes (2012) 1.47
Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J Gen Virol (2002) 1.46
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Curr Med Res Opin (2013) 1.44
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine (2006) 1.43
Changes in Problem-Solving Capacity and Association With Spontaneous Brain Activity After a Single Electroconvulsive Treatment in Major Depressive Disorder. J ECT (2016) 1.39
Potential nectin-1 binding site on herpes simplex virus glycoprotein d. J Virol (2005) 1.39
In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa. J Virol (2004) 1.39
Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res (2007) 1.35
The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J Biol Chem (2002) 1.35
Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host. J Immunol (2006) 1.34
K-bZIP of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) binds KSHV/HHV-8 Rta and represses Rta-mediated transactivation. J Virol (2003) 1.32
Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology (2005) 1.32
Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol (2012) 1.31
Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection. Proc Natl Acad Sci U S A (2007) 1.31
Contribution of cysteine residues to the structure and function of herpes simplex virus gH/gL. Virology (2005) 1.27